Dapagliflozin tablets – changes to reimbursement from September 2025

Dapagliflozin 5mg and 10mg tablets will be moving from Category C to Category M in the September 2025 Drug Tariff.

This comes after several manufacturers launched generic versions of Dapagliflozin tablets following the recent ruling by the UK Court of Appeal to invalidate AstraZeneca’s patent for the brand Forxiga^®.

Currently, all branded and generically written prescriptions for Dapagliflozin tablets are reimbursed in line with NHS list prices of the brand Forxiga^®. However, in September 2025, reimbursement of generically written prescriptions for Dapagliflozin tablets will be based on the Category M prices published in the September 2025 Drug Tariff. The Category M prices are calculated using actual market data obtained from suppliers.

The Department of Health and Social Care (DHSC) is making these changes outside the usual Category M quarterly cycle (Category M prices are normally updated every quarter in January, April, July, and October). Ahead of the Drug Tariff changes in September, pharmacy owners are advised to review and manage their brand and generic stockholding of Dapagliflozin tablets. DHSC was unable to give advance notice of these changes in the August Drug Tariff as the generics entered the market at the start of August.

The September Drug Tariff will be published on NHSBSA’s website at the end of August (typically three working days before the 1st of September). All other July to September 2025 Category M prices will remain unchanged.

Note: All generic Dapagliflozin prescriptions submitted in August will continue to be reimbursed in line with the August 2025 Drug Tariff. All branded prescriptions will continue to be reimbursed in line with the NHS list prices of Forxiga^®.